都市激情在线亚洲国产91_欧美日韩国产国语对白_av成人毛片在线免费观看_少妇爆乳无码专区网站_亚洲Aⅴ无码吞精久久AV_亚洲AV毛片一区无码日韩_国产成人精品1024视频网站_最新综艺节目国产精品喷浆_国产在线拍揄自揄视频网站_天天少妇被猛烈进入在线播放

3358288340
CN
CN EN
Open a new chapter, shape a creative future. Warm congratulations on the successful listing of Kexing Biopharm today

Release date:2020 - 12 - 14

On the morning of December 14, 2020, Kexing Biopharm (stock code: 688136) was officially listed on the Sci-Tech Innovation Board. The listing ceremony was held in the Shanghai Stock Exchange, and attended by the following: Bian Xiangwei, Deputy Secretary and Director of Zhangqiu District Committee of Jinan City; Huang Bo, Deputy Secretary of Party Working Committee and Director of Management Committee of Mingshui Economic and Technological Development Zone; representatives of intermediary agencies, clients, suppliers, shareholders and employee representatives.



Deng Xueqin, chairman of Kexing Biopharm, said at the listing ceremony that the successful listing was an important strategic measure for Kexing Biopharm to become a "leader in the industry of high-quality biopharmaceuticals" and was a major milestone in the company history. The state places great hopes on scientific innovation. Kexing Biopharm will select development platforms and seize the opportunities brought by this listing, make full use of capital force, further improve its innovation ability, and provide patients with biotechnologies. It is committed to becoming a leading innovative biopharmaceutical enterprise in China. It will return the trust and support of the majority of investors and all sectors of society with excellent performance, and make contributions to the high-quality development of the Chinese pharmaceutical industry!


Address by Deng Xueqin, Chairman of Kexing Biopharm


China Securities Co., Ltd. was the sponsor and lead underwriter for the listing of Kexing Biopharm. Liu Naisheng, a member of the Executive Committee of China Securities, gave his warmest congratulations as a representative. He said that Kexing Biopharm was one of the first domestic practitioners in biomedical innovation and pioneers in commercial production, who witnessed the birth, development and growth of biomedicine in China. Kexing Biopharm's Recombinant Human Interferon is a broad-spectrum antiviral drug and has been used to fight against SARS and COVID-19 as a core product, playing a role in epidemic prevention and control and following the original aspiration of pharmaceuticals. In the new development stage, Kexing Biopharm has got access to the capital market. Adhering to the mission of "Precise Products, Predictable Effects and Health Protection", it stayed focus on biopharmaceuticals. With the help of capital force, it will certainly grow into one of the core forces of biomedical innovation in China.


Address by Liu Naisheng, A Member of Executive Committee of China Securities


Bian Xiangwei, Deputy Secretary and Director of Zhangqiu District Committee of Jinan City expressed warm congratulations to Kexing Biopharm on behalf of Zhangqiu District Committee and Government. He said that the successful listing of Kexing Biopharm set an example for enterprises in the district and enhanced their confidence. With the great support of the capital market, Kexing Biopharm will be able to maintain a momentum of rapid growth, becoming a leading enterprise in the pharmaceutical industry.


Address by Bian Xiangwei, Deputy Secretary and Director of Zhangqiu District Committee of Jinan City


Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of therapeutic recombinant proteins, modified proteins, fusion proteins and micro-ecological drug products. It focuses on pharmaceutical research in the fields of antiviral, oncology and immunology, hematology, and digestive system. The products on sale include "Recombinant Human Erythropoietin" (EPOSINO), "Recombinant Human Interferon α1b" (SINOGEN), "Recombinant Human Granulocyte Colony-stimulating Factor" (WHITE-C), and "Combined Clostridium Butyricum and Bifidobacterium" (CLOBICO).


From 2017 to 2019, Kexing Biopharm achieved a revenue of RMB 616 million, RMB 891 million and RMB 1191 million, respectively, and a net profit attributable to shareholders of RMB 59,391,600, RMB 94,163,700 and RMB 159,810,400, respectively. From 2017 to 2019, Kexing Biopharm reached a compound revenue growth rate of 39.05%, and also achieved a substantial rise in net profit.


As a biopharmaceutical enterprise mainly engaged in the production of biopharmaceuticals with pure quality, Kexing Biopharm earned revenues mainly from Recombinant Human Erythropoietin and Recombinant Human Interferon α1b, RMB 559 million and RMB 353 million in 2019, respectively, accounting for 46.99% and 29.65% of gross revenue, respectively.


According to the statistical data of MENET, Kexing Biopharm's Recombinant Human Interferon α1b realized a market share of 21.45%, 23.95% and 26.29% in 2017, 2018 and 2019, respectively, ranking second in the domestic market of short-acting recombinant human interferon for injection.


Recombinant Human Erythropoietin (EPOSINO) achieved a market share of 9.36%, 11.27% and 12.51% in 2017, 2018 and 2019, respectively, ranking third in the domestic market. In addition, EPOSINO was obviously superior to other domestic products of the same type in terms of export business and has been approved for access to and sales in more than 20 countries.


With over two decades of experience in pharmaceutical research and commercial production technology since the establishment, Kexing Biopharm has had 3 major technology systems (prokaryotic cell technology, eukaryotic cell technology and viable micro-ecological bacteria technology), and has set up 5 world-leading platforms for strain technology, recombinant protein pharmaceutical industrialization technology, micro-ecological drug product R&D and industrialization technology, recombinant protein secretion and expression technology, and long-acting recombinant protein technology). Kexing Biopharm has obtained 36 patents, with 8 biopharmaceutical projects under research, including 2 projects of Class I innovative drugs.


Following the mission of "Precise Products, Predictable Effects and Health Protection", Kexing Biopharm is devoted to providing patients with biotechnologies, becoming a leading innovative biopharmaceutical enterprise in China.


国产午夜精品片一区二区三区 | 国产性生大片免费观看性 | 麻豆精产国品一二三产区区农民 | 国产精品久久久久一级 | 黄色一级片免费网站 | 推油少妇久久99久久99久久 | 久久线看在观草草青青脱裤 | 欧美一级a人与一级A片在线观看 | 国产黄色在线网站 | 性生生活大片又黄又 | 欧美精品免费一区二区三区 | 最近中文字幕免费MV视频 | 日韩成人在线网站 | 日韩欧美高清一区 | 久久狠狠爱亚洲综合影院 | 国产超碰人人爱被IOS解锁 | 97在线精品国自产拍中文 | 免费观看黄色毛片 | 成人免费毛片内射美女-百度 | 兰桂坊人成社区亚洲精品 | 日韩一级视频在线观看播放 | 日本丰满熟妇被捏出奶水 | 伊人久久精品中文字幕 | 无码一区二区三区视频 | 浪荡女天天不停挨CAO日常视频 | 欧美群交射精内射颜射潮喷 | 国产天堂亚洲国产碰碰 | 青青国产成人久久111网站 | 一级毛片久久久久久久女人18 | 欧美XXXXX高潮喷水麻豆 | 成人国产经典视频在线观看 | 国产精品一区在线观看你懂的 | 国产永久免费观看久久黄AV片 | 精品国产天堂综合一区在线 | **一级毛片全部免 | 3d无尽的性人妖 | 人妻少妇精品无码专区喷水 | 又黑又粗大棒插白妇口视频 | 最近高清中文字幕无吗免费看 | 蜜桃TV成人网站免费打开 | 国产乱老熟视频乱老熟女51 |